About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Sun Pharmaceutical Industries Ltd.
Change Company
BSE Code
524715
ISIN Demat
INE044A01036
Book Value
102.19
NSE Code
SUNPHARMA
Dividend Yield %
0.85
Market Cap
4537502.33
P/E
112.77
EPS
16.77
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
27-Apr-2026
Sun Pharmaceutical to acquire all outstanding sha...
27-Apr-2026
Sun Pharmaceutical Industries informs about inves...
27-Apr-2026
Sun Pharmaceutical Industries informs about press...
27-Apr-2026
Sun Pharmaceutical zooms on inking pact to acquir...
18-Apr-2026
Sun Pharmaceutical Industries informs about compl...
10-Apr-2026
Clarification sought from Sun Pharmaceutical Ind...
21-Mar-2026
Sun Pharmaceutical launches semaglutide injection...
21-Mar-2026
Sun Pharmaceutical Industries informs about press...
17-Mar-2026
Sun Pharmaceutical secures USFDA’s nod for review...
17-Mar-2026
Sun Pharmaceutical rises on securing USFDA’s nod ...
16-Mar-2026
Sun Pharmaceutical Industries informs about press...
01-Feb-2026
Sun Pharma reports 16% rise in Q3 consolidated ne...
01-Feb-2026
Sun Pharma gains on reporting 16% rise in Q3 cons...
01-Feb-2026
Sun Pharmaceutical Industries informs about newsp...
23-Jan-2026
Sun Pharma gets DCGI’s nod to manufacture, market...
Page
1
of
3
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.